Boston Scientific has struck a deal to buy medical-device maker Silk Road Medical for about $1.26 billion, adding a technology for stroke prevention to its vascular portfolio.

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Boston Globe Its stock is up 50 percent. Billion-dollar deals for breakfast. How did Boston Scientific get its mojo back? “It’s been a brick by brick, constant improvement, strengthening ...

Boston Scientific said on Wednesday it has discontinued sales of its heart device in the European Union and will not seek approval in the U.S. and other markets due to increased clinical and ...

Boston Scientific's earnings growth may slow to the low teens, making current P/E multiples hard to justify. See why BSX stock is a Hold.

Boston Scientific Q4 revenue rose 22.4% Y/Y to $4.56B, exceeding the $4.424B consensus. Adjusted EPS of $0.70 beat expectations of $0.66. Cardiovascular sales grew 28.8% to $2.94B, with cardiology ...

Boston Scientific developed a system: Set aside 10 percent of revenue for research and development, including to advance already acquired technologies, and devote much of its profits to new deals.

Medical devices maker Boston Scientific said on Tuesday it would buy private medical tech company Relievant Medsystems for an upfront cash payment of $850 million, gaining access to an FDA-cleared ...

Medical-products company Boston Scientific reported third-quarter results before market open Last Updated: Oct. 23, 2024 at 7:39 a.m. ET First Published: Oct. 23, 2024 at 6:55 a.m. ET Share ...

Boston Scientific shares are up another 50%-plus since my last update, outperforming a strong med-tech sector that has risen close to 30% over that time (using the S&P Health Care Equipment Select ...

OPINION Why you should visit Boston’s ‘murder triangle’ People who would otherwise never go to these neighborhoods saw with their own eyes what was working and what the needs were.

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).